These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 19151540)
1. New topics in vasopressin receptors and approach to novel drugs: involvement of vasopressin V1a and V1b receptors in nociceptive responses and morphine-induced effects. Honda K; Takano Y J Pharmacol Sci; 2009 Jan; 109(1):38-43. PubMed ID: 19151540 [TBL] [Abstract][Full Text] [Related]
2. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. Egashira N; Mishima K; Iwasaki K; Oishi R; Fujiwara M J Pharmacol Sci; 2009 Jan; 109(1):44-9. PubMed ID: 19151541 [TBL] [Abstract][Full Text] [Related]
3. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240 [TBL] [Abstract][Full Text] [Related]
4. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Koshimizu TA; Nakamura K; Egashira N; Hiroyama M; Nonoguchi H; Tanoue A Physiol Rev; 2012 Oct; 92(4):1813-64. PubMed ID: 23073632 [TBL] [Abstract][Full Text] [Related]
5. New topics in vasopressin receptors and approach to novel drugs: vasopressin and pain perception. Koshimizu TA; Tsujimoto G J Pharmacol Sci; 2009 Jan; 109(1):33-7. PubMed ID: 19151539 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574 [TBL] [Abstract][Full Text] [Related]
7. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling. Reymond-Marron I; Tribollet E; Raggenbass M Eur J Neurosci; 2006 Sep; 24(6):1565-74. PubMed ID: 17004920 [TBL] [Abstract][Full Text] [Related]
8. New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. Tanoue A J Pharmacol Sci; 2009 Jan; 109(1):50-2. PubMed ID: 19151542 [TBL] [Abstract][Full Text] [Related]
9. Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice. Peng F; Qu ZW; Qiu CY; Liao M; Hu WP Neurosci Lett; 2015 Apr; 593():61-5. PubMed ID: 25782631 [TBL] [Abstract][Full Text] [Related]
10. Subcellular localization and internalization of the vasopressin V1B receptor. Kashiwazaki A; Fujiwara Y; Tsuchiya H; Sakai N; Shibata K; Koshimizu TA Eur J Pharmacol; 2015 Oct; 765():291-9. PubMed ID: 26318147 [TBL] [Abstract][Full Text] [Related]
12. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806 [TBL] [Abstract][Full Text] [Related]
13. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Koshimizu TA; Nasa Y; Tanoue A; Oikawa R; Kawahara Y; Kiyono Y; Adachi T; Tanaka T; Kuwaki T; Mori T; Takeo S; Okamura H; Tsujimoto G Proc Natl Acad Sci U S A; 2006 May; 103(20):7807-12. PubMed ID: 16682631 [TBL] [Abstract][Full Text] [Related]
14. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936 [TBL] [Abstract][Full Text] [Related]
15. Role of vasopressin V1a receptor in ∆ Egashira N; Koushi E; Myose T; Tanoue A; Mishima K; Tsuchihashi R; Kinjo J; Tanaka H; Morimoto S; Iwasaki K Psychopharmacology (Berl); 2017 Dec; 234(23-24):3475-3483. PubMed ID: 28905207 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820 [TBL] [Abstract][Full Text] [Related]
17. Extrapituitary expression of the rat V1b vasopressin receptor gene. Lolait SJ; O'Carroll AM; Mahan LC; Felder CC; Button DC; Young WS; Mezey E; Brownstein MJ Proc Natl Acad Sci U S A; 1995 Jul; 92(15):6783-7. PubMed ID: 7624319 [TBL] [Abstract][Full Text] [Related]
18. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593 [TBL] [Abstract][Full Text] [Related]
19. Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors. Rodrigo J; Pena A; Murat B; Trueba M; Durroux T; Guillon G; Rognan D Mol Endocrinol; 2007 Feb; 21(2):512-23. PubMed ID: 17082326 [TBL] [Abstract][Full Text] [Related]
20. The bilevel chamber revealed differential involvement of vasopressin and oxytocin receptors in female mouse sexual behavior. Hayashi H; Shimizu K; Nakamura K; Nishimori K; Kondo Y PLoS One; 2024; 19(6):e0304703. PubMed ID: 38900750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]